ADVERTISEMENT

Highlights from the San Antonio Breast Cancer Symposium 2009: An Update

A recap of the 2008 San Antonio Breast Cancer Symposium. 

BY STAFF REPORTS
PUBLISHED WEDNESDAY, DECEMBER 8, 2010
Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
Many women develop breast tumors that are sensitive to estrogen—a female hormone that can feed a tumor’s growth and development. So for the past 15 years, researchers have experimented with hormonal drugs to figure out which drugs work best, how they should be sequenced (if giving more than one hormonal agent), and how long they should be taken.

In February 2008, Avastin (bevacizumab) received approval for metastatic breast cancer, despite the fact that an advisory panel for the FDA said the drug did not offer enough benefit (specifically in survival) to justify its use. Hoping to more clearly define the potential and the limits of the drug, researchers have continued testing Avastin in breast cancer, including as second-line therapy.

New data from the RIBBON-2 trial involved 684 women with HER2-negative metastatic breast cancer who had already received one course of chemotherapy. The women received another session of chemotherapy with or without Avastin.

The results: Adding Avastin to chemotherapy as a second-line treatment increased progression-free survival—the length of time the disease did not worsen—by approximately two months (from 5.1 months to 7.2 months). Furthermore, the RIBBON-2 study has not found an improvement in overall survival with the addition of Avastin, but 43 percent of women in the study were still alive.

In July, an FDA advisory panel met and recommended revoking the approval due to the disappointing results from RIBBON-2 and other more recent Avastin trials. A previous study had shown progression-free survival increase of about five months—data on which the FDA had originally based its accelerated approval decision. The FDA is expected to make a decision on Avastin by Dec. 17.

Read the full article here.

Scientists at the 2009 San Antonio Breast Cancer Symposium reported on women who initially started on the aromatase inhibitor Aromasin (exemestane) did no better than the women who switched to Aromasin later from tamoxifen. Regarding the likelihood of cancer recurring or a difference in survival, researcher Daniel Rea, MD, of the University of Birmingham said, "There is no difference whatsoever."

Another study examined whether being premenopausal at diagnosis made a difference in outcomes. All women were menopausal during the study, either naturally, because of surgical removal of the ovaries or because of chemotherapy treatment. Premenopausal women who took tamoxifen for five years, followed by another aromatase inhibitor called Femara (letrozole), were less likely to have a recurrence than women who took only tamoxifen for the initial five years. 

Read the full article here.

Taking Herceptin (trastuzumab) with, as opposed to after, chemotherapy helped more women live longer without a recurrence, new research found.

Investigators randomly assigned roughly 3,000 patients with stage 1 to stage 3 HER2-positive breast cancer who had already undergone surgery to receive either chemotherapy alone (Adriamycin [doxorubicin] and cyclophosphamide followed by Taxol [paclitaxel]), chemotherapy followed by Herceptin or chemotherapy given with Herceptin (paired with Taxol).

Talk about this article with other patients, caregivers, and advocates in the Breast CURE discussion group.
ADVERTISEMENT
ShareYourStory
Related Articles
Fear of Recurrence: Yes, I am Afraid My Cancer Will Come Back
A breast cancer survivor shares ways she copes with fear of recurrence while waiting for her latest mammogram results.
Are You Rushing Your Body to Heal?
Mending from cancer and its treatment takes time. It’s not always easy to let your body set the pace for recovery.
Treated With Herceptin? Read This
Herceptin has been one of the most remarkable breakthroughs in treating breast cancer — but it can cause cardiac issues.
Early Intervention Essential for Proper Management of Lymphedema
BY LAUREN M. GREEN
Early action to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.
Job's Friends
The best gift a friend can offer to someone who is ill is quiet comfort and support.
Related Videos
Health Advocate Amy Byer Shainman Discusses Risk Management of Hereditary Cancers
When it comes to managing your risk of cancer, especially when dealing with a familial cancer risk, "what is right for one person, may not be right for another," says Amy Byer Shainman.
Research Updates on HER2-Positive Breast Cancer from the 2015 Miami Breast Cancer Conference
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Medical Updates from the 32nd Annual Miami Breast Cancer Conference
The evolution of the treatment for hormone receptor-positive breast cancer was a hot topic for this year's Miami Breast Cancer Conference. Debu Tripathy, CURE's editor-in-chief and breast oncologist, reports from the meeting.
Joan Lunden Discusses the Physical and Emotional Effects of Breast Cancer Treatment
Journalist Joan Lunden shares her experience with breast cancer, side effects and working through treatment.
Journalist Joan Lunden Discusses Her Breast Cancer Diagnosis and Treatment
Roy Firestone interviews longtime journalist, author and television host Joan Lunden on her recent breast cancer diagnosis and treatment.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
$auto_registration$